Alamar Biosciences (NASDAQ:ALMR) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Alamar Biosciences (NASDAQ:ALMR) posted its quarterly earnings results on Tuesday. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.14, Zacks reports. The business had revenue of $29.43 million during the quarter.

Alamar Biosciences Stock Performance

Shares of ALMR opened at $33.12 on Thursday. Alamar Biosciences has a 12 month low of $18.84 and a 12 month high of $38.54. The firm has a 50 day simple moving average of $25.14. The firm has a market capitalization of $2.30 billion and a price-to-earnings ratio of -19.03.

Wall Street Analysts Forecast Growth

ALMR has been the subject of a number of recent research reports. TD Cowen reiterated a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Weiss Ratings started coverage on shares of Alamar Biosciences in a research note on Tuesday. They set a “sell (d+)” rating on the stock. Wall Street Zen raised shares of Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. Stifel Nicolaus increased their price target on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Alamar Biosciences from $32.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $31.80.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.